Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.

Antimicrobial agents and chemotherapy - 1 Feb 2003

Watkins Terri, Resch Wolfgang, Irlbeck David, Swanstrom Ronald

Abstract excerpt

Protease inhibitors represent some of the most potent agents available for therapeutic strategies designed to inhibit human immunodeficiency virus type 1 (HIV-1) replication. Under certain circumstances the virus develops resistance to the inhibitor, thereby negating the benefits of this therapy. We have carried out selections for high-level resistance to each of three protease inhibitors (indinavir, ritonavir,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cells, Cultured
Share to Drug Resistance, Viral
Share to HIV-1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Indinavir

Share to Ritonavir

Share to Saquinavir

Source

Open in PubMed Open full text

Identifiers

PMID: 12543689
DOI: 10.1128/AAC.47.2.759-769.2003
PMCID: PMC151730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.PMID 12543689Read ↗

Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug.Semantic proximity Read ↗

In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.Semantic proximity Read ↗

Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of DrugSemantic proximity Read ↗

Protease inhibitor resistance update: where are we now?Semantic proximity Read ↗

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.Semantic proximity Read ↗

Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.Semantic proximity Read ↗

Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.Semantic proximity Read ↗

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

Resistance to protease inhibitors.Semantic proximity Read ↗

Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.Semantic proximity Read ↗

Rapid genetic selection of inhibitor-resistant protease mutants: clinically relevant and novel mutants of the HIV protease.Semantic proximity Read ↗

HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.